BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 07, 2006
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/4 cls
Adolor (ADLR) Cowen Joshua Schimmer New Market outperform 8% $25.76
Schimmer believes positive Phase III data in 2H06 for Entereg alvimopan to treat chronic opioid bowel dysfunction will boost ADLR shares. He is less enthusiastic about Entereg for postoperative ileus (POI), which he views as having only modest sales potential. The selective peripherally acting mu opioid receptor antagonist, which has a Nov. 9 PDUFA date for POI, is partnered with GlaxoSmithKline (LSE:GSK; GSK).
Avanir (AVNR) ThinkEquity Andrew McDonald New Buy -4% $6.55
McDonald set a $9 target. He believes Neurodex will be approved to treat involuntary emotional expression disorder (pseudobulbar affect) despite the risk surrounding QT issues. In June, FDA extended Neurodex's PDUFA date by 90 days to Oct. 30 from July 30 to review a recently completed QT study.
BioMarin (BMRN; SWX:BMRN) Cowen Phil Nadeau Other Market outperform 6%

Read the full 903 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >